Stock Market Live May 5, 2026: S&P 500 (SPY) Bounces on Pullback in Oil

Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5864 Articles

John Harrington | Jun 29, 2017 at 10:45 AM EDT

Study Shows Alaskans Spend Most on Drugs per Day

A new report details the extent of Americans’ drug consumption, which are the narcotics of choice, which states' residents spend…

Chris Lange | Jun 27, 2017 at 11:10 AM EDT

Bluebird Bio Gears Up for $350 Million Offering

Bluebird Bio shares have made a steady gain over the course of the year and now the firm is looking…

Lee Jackson | Jun 27, 2017 at 10:20 AM EDT

Analyst Predicts Major Short Squeeze in 4 Biotech Stocks to Buy

Many on Wall Street feel that some of the more speculative institutional tech money may be rotating into the biotechs,…

Chris Lange | Jun 27, 2017 at 8:50 AM EDT

Major Biotech Short Interest Surges

The June 15 short interest data have been compared with the previous report, and short interest in most of the…

Chris Lange | Jun 27, 2017 at 8:45 AM EDT

Short Sellers Run for Cover From Major Pharma

The June 15 short interest data have been compared with the previous figures, and short interest in most of these…

Chris Lange | Jun 26, 2017 at 11:05 AM EDT

Agio Pharma Sinks on Midstage Trial

Agio Pharmaceuticals saw its shares sink on Monday after the firm announced results from its midstage trial for the treatment…

Chris Lange | Jun 23, 2017 at 10:50 AM EDT

Cara Therapeutics Wins Big on FDA Breakthrough

Cara Therapeutics saw its shares rise on Friday after the company said that the FDA granted a Breakthrough Therapy designation…

Chris Lange | Jun 22, 2017 at 9:30 AM EDT

Jefferies Sees 6 Biotechs as Undervalued With Massive Upside

Jefferies has picked out a few companies in the biotech industry that stand to win big over the coming year.

Chris Lange | Jun 21, 2017 at 1:20 PM EDT

Clovis Looks to Cash in on Secondary Offering

Clovis Oncology saw its shares make a handy gain in Wednesday’s session after the company priced its secondary offering.

Jon C. Ogg | Jun 21, 2017 at 12:15 PM EDT

Does Eiger BioPharmaceuticals Really Have 400% Upside?

Why do so many analysts on Wall Street have such massive upside targets for a speculative stock such as Eiger BioPharmaceuticals.

Chris Lange | Jun 20, 2017 at 12:20 PM EDT

Neos Therapeutics Slides Despite FDA Approval

Neos Therapeutics saw its shares dip on Tuesday even thought it received approval from the FDA for its treatment of…

Jon C. Ogg | Jun 20, 2017 at 10:45 AM EDT

Large Insider Buying at Alexion Raises Investors’ Eyebrows

Most of the large biotech outfits in America have gone into a limbo mode. Alexion Pharmaceuticals fits that bill despite…

Chris Lange | Jun 20, 2017 at 10:15 AM EDT

Egalet Stumbles Over FDA Complete Response Letter

Egalet saw its shares take a dive early on Tuesday after the company announced that it received a complete response…

Chris Lange | Jun 20, 2017 at 9:59 AM EDT

Dova Pharmaceuticals Closes in on IPO

Dova Pharmaceuticals intends to price its about 4 million shares in the range of $15 to $17 in an initial…

Chris Lange | Jun 20, 2017 at 8:35 AM EDT

Akcea Therapeutics Announces Potential Pricing for IPO

Akcea Therapeutics expects to price more than 9 million shares in the range of $12 to $14 apiece in an…

1 … 162 163 164 165 166 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Study Shows Alaskans Spend Most on Drugs per Day

Bluebird Bio Gears Up for $350 Million Offering

Analyst Predicts Major Short Squeeze in 4 Biotech Stocks to Buy

Major Biotech Short Interest Surges

Short Sellers Run for Cover From Major Pharma

Agio Pharma Sinks on Midstage Trial

Cara Therapeutics Wins Big on FDA Breakthrough

Jefferies Sees 6 Biotechs as Undervalued With Massive Upside

Clovis Looks to Cash in on Secondary Offering

Does Eiger BioPharmaceuticals Really Have 400% Upside?

Neos Therapeutics Slides Despite FDA Approval

Large Insider Buying at Alexion Raises Investors’ Eyebrows

Egalet Stumbles Over FDA Complete Response Letter

Dova Pharmaceuticals Closes in on IPO

Akcea Therapeutics Announces Potential Pricing for IPO

Stock Market Live May 5, 2026: S&P 500 (SPY) Bounces on Pullback in Oil

Live Nasdaq Composite: Tech Stock Gains Unleashed as Stars Align for Risk-On Trade

Up 160% in One Month, This AI ETF Can Still 5X

Here’s Where CoreWeave Proves the Doubters Wrong Once and For All

Want Income Without Betting The Farm On Interest Rates? Read This

Seven Out of Every Ten Dollars of Americans $18.8 Trillion Debt Is Tied To A House

A $1.25 Million Dividend Portfolio That Pays More Than the Average Teacher Earns in a Year

Up 160% in One Month, This AI ETF Can Still 5X

Here’s Where CoreWeave Proves the Doubters Wrong Once and For All

Health and Healthcare Articles

All Health and Healthcare Articles

Study Shows Alaskans Spend Most on Drugs per Day

Bluebird Bio Gears Up for $350 Million Offering

Analyst Predicts Major Short Squeeze in 4 Biotech Stocks to Buy

Major Biotech Short Interest Surges

Short Sellers Run for Cover From Major Pharma

Agio Pharma Sinks on Midstage Trial

Cara Therapeutics Wins Big on FDA Breakthrough

Jefferies Sees 6 Biotechs as Undervalued With Massive Upside

Clovis Looks to Cash in on Secondary Offering

Does Eiger BioPharmaceuticals Really Have 400% Upside?

Neos Therapeutics Slides Despite FDA Approval

Large Insider Buying at Alexion Raises Investors’ Eyebrows

Egalet Stumbles Over FDA Complete Response Letter

Dova Pharmaceuticals Closes in on IPO

Akcea Therapeutics Announces Potential Pricing for IPO

Stock Market Live May 5, 2026: S&P 500 (SPY) Bounces on Pullback in Oil

Live Nasdaq Composite: Tech Stock Gains Unleashed as Stars Align for Risk-On Trade

Up 160% in One Month, This AI ETF Can Still 5X

Here’s Where CoreWeave Proves the Doubters Wrong Once and For All

Want Income Without Betting The Farm On Interest Rates? Read This

Featured Reads

Seven Out of Every Ten Dollars of Americans $18.8 Trillion Debt Is Tied To A House

A $1.25 Million Dividend Portfolio That Pays More Than the Average Teacher Earns in a Year